Lung
This session provides clinicians in practice and trainees with a comprehensive review and update of the clinical practice parameters in the multidisciplinary management of patients with lung cancer. The management of non-small cell lung cancer and small cell lung cancer is discussed, focusing on the role of radiotherapy in early-stage, locally advanced and metastatic disease. Key evidence that forms the basis for current clinical practice guidelines and emerging trends in practice patterns is also reviewed.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Implement radiotherapy in the management of patients with non-small cell lung cancer following evidence-based practices.
- Implement radiotherapy in the management of patients with small cell lung cancer following evidence-based practices.
Planning Committee Disclosures
The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.